On February 11, Aimi Vaccines (06660) issued an announcement that the company recently applied to the Drug Review Center of the China Food and Drug Administration for clinical trials of mRNA herpes zoster vaccines. According to the announcement, the company's mRNA herpes zoster vaccine showed that specific T cell immunity, IgG antibody titers and membrane antigen fluorescent antibody titers were significantly higher than the commercially available recombinant subunit control vaccine in preclinical animal trials. This shows that the vaccine has obvious advantages in immune protection.

In addition, the announcement mentioned that the particularity of the herpes zoster virus makes it latent for life after the initial infection, and T cell-mediated immune protection is the key to controlling viral reactivation. At present, the vaccination rate of herpes zoster vaccine in the target population is only about 0.1%, and the market potential is huge. According to industry consultants, the market size of shingles vaccine in China is expected to reach about 20 billion yuan and the global market size is expected to reach about 23.9 billion US dollars by 2030. If the product is approved for marketing, it will bring considerable performance growth to the company.

https://finance.eastmoney.com/a/202502113316334912.html